Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial.
Peterlin P, Garnier A, Le Bourgeois A, Guillaume T, Le Bris Y, Theisen O, Béné MC, Eveillard M, Rimbert M, Jullien M, Planche L, Gaschet J, Chevallier P. Peterlin P, et al. Among authors: gaschet j. EClinicalMedicine. 2023 Sep 28;64:102254. doi: 10.1016/j.eclinm.2023.102254. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37786451 Free PMC article.
A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Godon C, Mahé B, Dubruille V, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Tessoulin B, Le Gouill S, Moreau P, Béné MC, Chevallier P. Peterlin P, et al. Among authors: gaschet j. Cancer Med. 2021 Jan;10(2):642-648. doi: 10.1002/cam4.3648. Epub 2020 Dec 25. Cancer Med. 2021. PMID: 33369136 Free PMC article.
FLT3 ligand plasma levels in acute myeloid leukemia.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P. Peterlin P, et al. Among authors: gaschet j. Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. Haematologica. 2019. PMID: 30630980 Free PMC article. No abstract available.
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F. Chevallier P, et al. Among authors: gaschet j. Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25. Lancet Haematol. 2015. PMID: 26687796 Clinical Trial.
FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P. Peterlin P, et al. Among authors: gaschet j. Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28. Cytokine. 2019. PMID: 31035172 Clinical Trial.
Radioimmunotherapy for Treatment of Acute Leukemia.
Bodet-Milin C, Kraeber-Bodéré F, Eugène T, Guérard F, Gaschet J, Bailly C, Mougin M, Bourgeois M, Faivre-Chauvet A, Chérel M, Chevallier P. Bodet-Milin C, et al. Among authors: gaschet j. Semin Nucl Med. 2016 Mar;46(2):135-46. doi: 10.1053/j.semnuclmed.2015.10.007. Semin Nucl Med. 2016. PMID: 26897718 Review.
Preclinical Evaluation of a 64Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma.
Métivier C, Le Saëc P, Gaschet J, Chauvet C, Marionneau-Lambot S, Hofgaard PO, Bogen B, Pineau J, Le Bris N, Tripier R, Alliot C, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L. Métivier C, et al. Among authors: gaschet j. Pharmaceutics. 2023 Jun 25;15(7):1817. doi: 10.3390/pharmaceutics15071817. Pharmaceutics. 2023. PMID: 37514004 Free PMC article.
Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.
Rousseau C, Ruellan AL, Bernardeau K, Kraeber-Bodéré F, Gouard S, Loussouarn D, Saï-Maurel C, Faivre-Chauvet A, Wijdenes J, Barbet J, Gaschet J, Chérel M, Davodeau F. Rousseau C, et al. Among authors: gaschet j. EJNMMI Res. 2011 Sep 1;1(1):20. doi: 10.1186/2191-219X-1-20. EJNMMI Res. 2011. PMID: 22214534 Free PMC article.
Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease.
Gouard S, Maurel C, Marionneau-Lambot S, Dansette D, Bailly C, Guérard F, Chouin N, Haddad F, Alliot C, Gaschet J, Eychenne R, Kraeber-Bodéré F, Chérel M. Gouard S, et al. Among authors: gaschet j. Cancers (Basel). 2020 Sep 22;12(9):2721. doi: 10.3390/cancers12092721. Cancers (Basel). 2020. PMID: 32971984 Free PMC article.
Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.
Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, Gaschet J, Chérel M. Fichou N, et al. Among authors: gaschet j. Front Med (Lausanne). 2015 Nov 4;2:76. doi: 10.3389/fmed.2015.00076. eCollection 2015. Front Med (Lausanne). 2015. PMID: 26582128 Free PMC article.
50 results